Psyence BioMed unit signs term sheet with PsyLabs for exclusive U.S. ibogaine license, supply deal
Bitget2026/09/28 11:01- Psyence Biomedical entered a binding term sheet with PsyLabs for exclusive U.S. rights to pharmaceutical-grade ibogaine via its Texas unit.
- Texas Ibogaine Research Corporation would receive exclusive development, supply, wholesale distribution rights, subject to a definitive agreement by Nov. 30, 2026.
- PsyLabs would remain the exclusive supplier; the license includes manufacturing know-how, specifications, technical documentation for ibogaine hydrochloride.
- Consideration includes up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
- Additional economics include a low single-digit royalty on net sales, an annual exclusivity fee after first FDA approval, and margin-sharing on resale.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nikkei 225 Index surpasses 70,000 points for the first time since July 6
NIL has surged more than 17% in 24 hours, and the current price is 0.096 USDT.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Current Spread in Yield Basis Points Germany 3.475 % Australia 5.347 % 187.2 Belgium 4.339 % 86.4 Canada 3.944 % 46.9 Denmark 3.268 % -20.7 France 4.866 % 139.1 Italy 4.604 % 113.0 Japan 3.100 % -37.5 Netherlands 3.577 % 10.2 Spain 4.087 % 61.2 Sweden 3.146 % -32.9 U.K. 5.369 % 189.4 U.S. 5.267 % 179.2 Source: Tullett Prebon via FactSet (END) Dow Jones Newswires October 04, 2026 21:10 ET (01:10 GMT)
‘Ethereum risks being left behind’ – Analysts debate L1’s role in tokenization boom
